ASH 2024: CLL Updates

By
Kerry Rogers, MDPaul Hampel, MDCatherine Callaghan Coombs, MD
From the 2024 ASH Annual Meeting & Exposition, experts discuss current treatment options, new combinations and which parents should consider CAR T-cell therapy.

From the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, Kerry Rogers, MD, is joined by Paul Hampel, MD, and Catherine Coombs, MD, to discuss current chronic lymphocytic leukemia treatment options, new combinations and which parents should consider CAR T-cell therapy.

Dr. Kerry Rogers
Chronic Lymphocytic Leukemia

The Current Treatment Landscape for CLL

From the 2024 ASH Annual Meeting & Exposition, experts discuss current treatment options for those who have previously been treated for CLL.

Dr. Kerry Rogers
Chronic Lymphocytic Leukemia

The Current Treatment Landscape for CLL

From the 2024 ASH Annual Meeting & Exposition, experts discuss current treatment options for those who have previously been treated for CLL.

Catherine Coombs, MD
Chronic Lymphocytic Leukemia

Second Gen BTKs: Who Do They Benefit?

From the 2024 ASH Annual Meeting & Exposition, experts discuss “second generation” BTK inhibitors and which CLL patients might benefit from new combinations.

Catherine Coombs, MD
Chronic Lymphocytic Leukemia

Second Gen BTKs: Who Do They Benefit?

From the 2024 ASH Annual Meeting & Exposition, experts discuss “second generation” BTK inhibitors and which CLL patients might benefit from new combinations.

Kerry Rogers, MD, is joined by Paul Hampel, MD, and Catherine Coombs, MD
Chronic Lymphocytic Leukemia

Pirtobrutinib: How it Differs

From the 2024 ASH Annual Meeting & Exposition, experts discuss how pirtobrutinib is different from other BTK inhibitors and how it fits into CLL treatments.

Kerry Rogers, MD, is joined by Paul Hampel, MD, and Catherine Coombs, MD
Chronic Lymphocytic Leukemia

Pirtobrutinib: How it Differs

From the 2024 ASH Annual Meeting & Exposition, experts discuss how pirtobrutinib is different from other BTK inhibitors and how it fits into CLL treatments.

Dr. Paul Hampel
Chronic Lymphocytic Leukemia

Is CAR T-Cell Therapy Curative?

Is CAR T-cell therapy curative? From the 2024 ASH Annual Meeting & Exposition, experts discuss when a patient with CLL should consider CAR T-cell therapy.

Dr. Paul Hampel
Chronic Lymphocytic Leukemia

Is CAR T-Cell Therapy Curative?

Is CAR T-cell therapy curative? From the 2024 ASH Annual Meeting & Exposition, experts discuss when a patient with CLL should consider CAR T-cell therapy.

Kerry Rogers, MD, is joined by Paul Hampel, MD, and Catherine Coombs, MD
Chronic Lymphocytic Leukemia

Epcoritamab: How Does it Work?

From the 2024 ASH Annual Meeting & Exposition, experts discuss the potential side effects of epcoritamab and which CLL patients should consider this treatment.

Kerry Rogers, MD, is joined by Paul Hampel, MD, and Catherine Coombs, MD
Chronic Lymphocytic Leukemia

Epcoritamab: How Does it Work?

From the 2024 ASH Annual Meeting & Exposition, experts discuss the potential side effects of epcoritamab and which CLL patients should consider this treatment.